Smith Mitchell R
Lymphoma Service, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA.
Cancer J. 2008 May-Jun;14(3):184-90. doi: 10.1097/PPO.0b013e318173a5f9.
Over the last decade, monoclonal antibody therapy has transformed treatment of many hematologic malignancies. Optimizing the use of the existing agents and developing new agents will be critical to continuing these advances. This review summarizes existing data, new agents under investigation, and areas in which progress needs to be made in understanding mechanisms of action and resistance.
在过去十年中,单克隆抗体疗法改变了许多血液系统恶性肿瘤的治疗方式。优化现有药物的使用并开发新药物对于延续这些进展至关重要。本综述总结了现有数据、正在研究的新药物,以及在理解作用机制和耐药性方面需要取得进展的领域。